C. Frank Bennett

C. Frank Bennett is one of the most consequential figures in the history of nucleic acid medicine, having spent more than three decades at Ionis Pharmaceuticals (formerly ISIS Pharmaceuticals) pioneering the chemistry, pharmacology, and clinical translation of antisense oligonucleotide (ASO) drugs. As Chief Scientific Officer, he has overseen the development of multiple FDA-approved ASO therapies and has built one of the most productive drug discovery platforms in modern pharmaceutical science. Bennett's central contribution is the systematic development of "gapmer" ASO chemistry — molecules in which a central stretch of DNA nucleotides capable of activating RNase H-mediated target RNA cleavage is flanked by nucleotides bearing chemical modifications (most notably 2'-methoxyethyl, constrained ethyl, or locked nucleic acid modifications) that dramatically enhance affinity, metabolic stability, and tissue distribution. These gapmer architectures transformed ASOs from research tools with poor pharmacokinetic profiles into robust drug candidates with once-monthly or less-frequent dosing. Among the approved drugs Bennett has championed are nusinersen (Spinraza, SMA), developed with Adrian Krainer and Biogen; tofersen (Qalsody), an ASO for SOD1-ALS reducing neurofilament light chain biomarkers; eplontersen (Wainua), a GalNAc-conjugated ASO targeting transthyretin for hereditary transthyretin amyloid polyneuropathy; and inclisiran (in co-development), a GalNAc-siRNA targeting PCSK9 for hypercholesterolemia. The LICA (ligand-conjugated antisense) platform, which Bennett led, uses N-acetylgalactosamine (GalNAc) conjugation to achieve hepatocyte-selective delivery via the asialoglycoprotein receptor. GalNAc-ASO conjugates achieve therapeutic exposures in liver at doses 30- to 60-fold lower than unconjugated ASOs, enabling subcutaneous self-administration and greatly expanding the hepatic disease indications addressable with ASO therapy. This platform has broad applicability to oncology, including targeting oncogenic drivers expressed predominantly in liver cancer cells. Bennett has also pioneered CNS ASO delivery, demonstrating that intrathecal or intracerebroventricular administration of naked ASOs achieves broad, durable distribution throughout the central nervous system — the pharmacological basis of nusinersen's clinical efficacy. He has extended this approach to preclinical programs targeting Huntington's disease (HTT), Alzheimer's disease (MAPT, APP), and glioblastoma.

C. Frank Bennett 是核酸医学史上最具影响力的人物之一，在爱奥尼斯制药公司工作超过三十年，系统开创了反义寡核苷酸（ASO）药物的化学、药理学和临床转化。作为首席科学官，他监督了多款 FDA 批准的 ASO 治疗药物的开发。 Bennett 的核心贡献是系统开发"Gapmer" ASO 化学——通过化学修饰侧翼（2'-甲氧乙基、约束乙基或锁核酸修饰）极大提高亲和力、代谢稳定性和组织分布，将 ASO 从药代动力学不佳的研究工具转变为可每月一次或更少频率给药的强效药物候选分子。 他主导的 LICA 平台利用 N-乙酰半乳糖胺（GalNAc）缀合实现肝细胞选择性递送，使治疗剂量降低30至60倍，显著拓展了 ASO 疗法可覆盖的肝脏疾病适应症。他同时开拓了 CNS ASO 递送，为 nusinersen、Huntington 病及胶质母细胞瘤等多个项目奠定了药理基础。